Skip to content
Advertisement

A worker opens a package of coronavirus vaccine made by a Sinopharm subsidiary during a COVID-19 vaccination session for resident foreign journalists at a vaccination center in Beijing, Tuesday, March 23, 2021. Chinese medical firm Sinovac said its COVID-19 vaccine is safe in children ages 3-17, based on preliminary data, and it has submitted the data to Chinese drug regulators. State-owned Sinopharm, who has two COVID-19 vaccines, is also investigating the effectiveness of its vaccines in children. (AP Photo/Mark Schiefelbein)

A worker opens a package of coronavirus vaccine made by a Sinopharm subsidiary during a COVID-19 vaccination session for resident foreign journalists at a vaccination center in Beijing, Tuesday, March 23, 2021. Chinese medical firm Sinovac said its COVID-19 vaccine is safe in children ages 3-17, based on preliminary data, and it has submitted the data to Chinese drug regulators. State-owned Sinopharm, who has two COVID-19 vaccines, is also investigating the effectiveness of its vaccines in children. (AP Photo/Mark Schiefelbein)

Featured Photo Galleries